Find relevant news articles from other European projects, below:
Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:
Therapeutic options for Treatment-Naïve Chronic Leukocytic Leukemia
During a virtual Targeted Oncology Case-Based Roundtable event, Daniel O. Persky, MD, reviewed the case of a 61-year-old patient with chronic lymphocytic leukemia.
Browse this week's featured selection of scientific publications
A new selection of scientific publications relating to the latest developments in immunotherapy are added to our website weekly. Here are are a few highlights from this week.
Cirmtuzumab/Ibrutinib Shows Encouraging Clinical Activity, Safety in MCL and CLL
Hun Ju Lee, MD, discusses a phase 1/2 study evaluating cirmtuzumab in combination with ibrutinib in patients with mantle cell lymphoma or chronic lymphocytic leukemia.
Ianalumab/Ibrutinib Combo Shows Promising Activity in CLL
Kerry A, Rogers, MD, discusses the rationale behind the phase 1b study of VAY736 combined with ibrutinib in patients with chronic lymphocytic leukemia and the next steps for this research.
Ianalumab add-on therapy in CLL patients receiving ibrutinib
Ian Flinn, MD, PhD, Tennessee Oncology, Nashville, TN, discusses a Phase Ib trial (NCT03400176) of ianalumab plus ibrutinib in patients with chronic lymphocytic leukemia (CLL) receiving ibrutinib therapy. Ianalumab (VAY736) is an anti-BAFF-R monoclonal antibody that causes antibody-dependent cellular cytotoxicity of B-cells.
Updates at ASH in CLL: U2 and ublituximab
Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, discusses his excitement for updates from the UNITY-CLL study which will be presented at ASH 2020.
ASH 2020 | TRANSCEND CLL 04: 18-month follow-up of liso-cel for R/R CLL
Daniel DeAngelo, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the findings of a trial (NCT03386513) of IMGN632, a novel antibody-drug conjugate (ADC), in relapsed/refractory (R/R) blastic plasmacytoid dendritic cell neoplasm (BPDCN), a setting with poor outcomes and minimal treatment options.
iwCAR-T meeting 2020: featured sessions
During iwCAR-T 2020, some of the world’s leading clinical researchers shared their perspectives on how to place our evolving understanding in a clinical context and thereby optimize clinical care.